593 related articles for article (PubMed ID: 35937834)
41. Effects of plasma apolipoproteins on lipoprotein lipase-mediated lipolysis of small and large lipid emulsions.
Yamamoto M; Morita SY; Kumon M; Kawabe M; Nishitsuji K; Saito H; Vertut-Doï A; Nakano M; Handa T
Biochim Biophys Acta; 2003 Jun; 1632(1-3):31-9. PubMed ID: 12782148
[TBL] [Abstract][Full Text] [Related]
42. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
[TBL] [Abstract][Full Text] [Related]
43. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
[TBL] [Abstract][Full Text] [Related]
44. Association Between Increased Lipid Profiles and Risk of Diabetic Retinopathy in a Population-Based Case-Control Study.
Liu Z; Shao M; Ren J; Qiu Y; Li S; Cao W
J Inflamm Res; 2022; 15():3433-3446. PubMed ID: 35711238
[TBL] [Abstract][Full Text] [Related]
45. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
Batal R; Tremblay M; Barrett PH; Jacques H; Fredenrich A; Mamer O; Davignon J; Cohn JS
J Lipid Res; 2000 May; 41(5):706-18. PubMed ID: 10787431
[TBL] [Abstract][Full Text] [Related]
46. Isolation and partial characterization of lipoprotein A-II (LP-A-II) particles of human plasma.
Bekaert ED; Alaupovic P; Knight-Gibson C; Norum RA; Laux MJ; Ayrault-Jarrier M
Biochim Biophys Acta; 1992 Jun; 1126(1):105-13. PubMed ID: 1606170
[TBL] [Abstract][Full Text] [Related]
47. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
Chan DC; Nguyen MN; Watts GF; Barrett PH
J Clin Endocrinol Metab; 2008 Feb; 93(2):557-64. PubMed ID: 18000086
[TBL] [Abstract][Full Text] [Related]
48. Serum levels of vasohibin-1 in type 2 diabetes mellitus patients with diabetic retinopathy.
Feng Y; Wang D; Liu Y; Pang X; Zhang H
Eur J Ophthalmol; 2022 Sep; 32(5):2864-2869. PubMed ID: 35001686
[TBL] [Abstract][Full Text] [Related]
49. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states.
Asztalos BF; Schaefer EJ; Horvath KV; Yamashita S; Miller M; Franceschini G; Calabresi L
J Lipid Res; 2007 Mar; 48(3):592-9. PubMed ID: 17183024
[TBL] [Abstract][Full Text] [Related]
50. Plasma high-density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume.
Pedrini S; Doecke JD; Hone E; Wang P; Thota R; Bush AI; Rowe CC; Dore V; Villemagne VL; Ames D; Rainey-Smith S; Verdile G; Sohrabi HR; Raida MR; Taddei K; Gandy S; Masters CL; Chatterjee P; Martins RN;
J Neurochem; 2022 Oct; 163(1):53-67. PubMed ID: 36000528
[TBL] [Abstract][Full Text] [Related]
51. Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids.
Sasongko MB; Wong TY; Nguyen TT; Kawasaki R; Jenkins A; Shaw J; Wang JJ
Diabetes Care; 2011 Feb; 34(2):474-9. PubMed ID: 21270203
[TBL] [Abstract][Full Text] [Related]
52. Plasma lipoproteins: apolipoprotein structure and function.
Mahley RW; Innerarity TL; Rall SC; Weisgraber KH
J Lipid Res; 1984 Dec; 25(12):1277-94. PubMed ID: 6099394
[TBL] [Abstract][Full Text] [Related]
53. Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.
Ikewaki K; Mochizuki K; Iwasaki M; Nishide R; Mochizuki S; Tada N
Metabolism; 2002 Oct; 51(10):1348-54. PubMed ID: 12370857
[TBL] [Abstract][Full Text] [Related]
54. Non-high-density lipoprotein cholesterol is associated more closely with albuminuria in Chinese type 2 diabetic patients with normal renal function, compared with traditional lipid parameters.
Pan J; Gao F; Bao Y; Zhang L; Tu Y; Jia W
J Clin Lipidol; 2012; 6(4):382-7. PubMed ID: 22836076
[TBL] [Abstract][Full Text] [Related]
55. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.
Kashyap ML; Srivastava LS; Hynd BA; Gartside PS; Perisutti G
J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286
[TBL] [Abstract][Full Text] [Related]
56. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV.
Goldberg IJ; Scheraldi CA; Yacoub LK; Saxena U; Bisgaier CL
J Biol Chem; 1990 Mar; 265(8):4266-72. PubMed ID: 2307668
[TBL] [Abstract][Full Text] [Related]
57. In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism.
Ikewaki K; Rader DJ; Zech LA; Brewer HB
J Lipid Res; 1994 Oct; 35(10):1809-19. PubMed ID: 7852858
[TBL] [Abstract][Full Text] [Related]
58. Relevance of the serum apolipoprotein ratio to diabetic retinopathy.
Deguchi Y; Maeno T; Saishin Y; Hori Y; Shiba T; Takahashi M
Jpn J Ophthalmol; 2011 Mar; 55(2):128-31. PubMed ID: 21400057
[TBL] [Abstract][Full Text] [Related]
59. The molecular biology of human apoA-I, apoA-II, apoC-II and apoB.
Law SW; Lackner KJ; Fojo SS; Hospattankar A; Monge JC; Brewer HB
Adv Exp Med Biol; 1986; 201():151-62. PubMed ID: 2432761
[TBL] [Abstract][Full Text] [Related]
60. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
Chan DC; Watts GF; Nguyen MN; Barrett PH
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):590-6. PubMed ID: 16410456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
